

**INTERIM REPORT
for I-III 2016
Group Medika**

April 2016

Management interim report

Comment on the business results for the first quarter of 2016

Medika Group („Group“) has realised total revenue in the first quarter of 2016 in amount of HRK 679.0 million which is by 9.89% higher comparing to the same period of previous year.

Sales revenues which amount to HRK 661.8 million for the first three months of 2016 are by 9.34% higher comparing to the same period of previous year.

Share of sales revenues in the total revenue is 97.46% and has not significantly changed comparing to the same period of previous year when it was 97.95%.

Other operating revenues which amount to HRK 5.4 million are lower comparing to the same period of previous year by HRK 2.0 million. Since the share of other operating revenues in total revenue was only 1.21% in the first three months of 2015, and in the first three months of 2016 is only 0.80%, this decrease is not that significant.

Out of the total sales revenues, 99.94% revenues are generated on domestic market, while 0.06% is generated on the foreign market. This structure in the first three months of 2016 is almost on same level comparing to the same period of previous year.

Material expenses amount to HRK 615.3 million and are by 8.93% higher comparing to the same period of previous year. Since the operating expenses are growing slower, share of material expenses in the operating expenses is by 0.54% higher comparing to the same period of previous year and amounts to 93.88%.

Employee expenses are by 3.14% higher comparing to the same period of previous year. Since operating expenses have increased more, their share in the operating expenses has decreased by 0.19%.

Finance expenses have increased compared to the same period of previous year by HRK 1.5 million, which is 40.70%. Their share in the total expenses is 0.81%, while in the same period of previous year it amounted to 0.62%. This increase is the result of higher interest expenses as a result of higher average indebtedness in the first three months of 2016 comparing to the same period of previous year.

Gross margin in the first three months of 2015 amounted to 8.49% while in the first three months of 2016 amounts to 8.70% which is increase of 0.21%. Increase is a result of larger increase in net sales revenue comparing to the increase in net cost of goods sold.

Gross profit (profit before taxation) amounts to HRK 18.3 million, while in the same period of previous year amounted to HRK 8.9 million, which is increase of HRK 9.3 million. Higher gross profit is result of greater increase of total income (increase of 9.89% comparing to the same period of previous year) in relation to the increase of total expenses (increase of 8.50% comparing to the same period of previous year).

Operative earnings amount to HRK 11.8 million and are by HRK 4.3 million, or 57.30%, higher comparing to the same period of previous year.

Realised net profit amounts to HRK 14.1 million.

Transactions with the related parties in the first three months of 2016 generated total revenue in amount of HRK 7.7 million, while in the same period of previous year total revenue amounted to HRK 7.4 million, which is increase of 3.08%.

Trade goods purchased from the related parties amount to HRK 56.1 million, while in the same period of previous year they amounted to HRK 31.4 million. Increase is result of increase in sales.

Total assets are by 5.45% higher comparing to the beginning of the year which is mostly influenced by increase of short term assets.

Long term assets are higher for HRK 6.3 million comparing to the beginning of the year. Long term intangible assets are higher comparing to the beginning of the year for HRK 3.7 million, which is a result of increase in goodwill due to purchase of Ljekarna Maja Mučaji and Ljekarna Mirija Bohunicki and merging of Ljekarna Smilja Bagat. Long term tangible assets have increased comparing to the beginning of the year for HRK 1.2 million. This is the result of increase in assets under construction that relate to changes in the warehouse.

Long term financial assets amounts to HRK 31.1 million and mostly relates to the investment in related parties.

Deferred tax assets are at the same level comparing to the beginning of the year.

Short term assets amount to HRK 1 billion 618.6 million and are by HRK 100.5 million, or 6.62%, higher comparing to the beginning of the year. In the structure of short term assets all balances (inventory, receivables and financial assets) have increased.

Inventory has increased by HRK 12.4 million comparing to the beginning of the year which is a result of higher procurement due to the sales increase.

Total short term receivables amount to HRK 1 billion 121.3 million and are higher for HRK 112.0 million, which is 11.09%, comparing to the beginning of the year. Trade receivables and receivables from related parties amount to HRK 1 billion 113.1 million and have increased by 11.19% comparing to the beginning of the year.

Short term financial assets amount to HRK 207.3 million and relates to short term given loans.

In equity there was change in treasury shares and capital reserves due to the granting of treasury shares to the management.

Short term liabilities amount to HRK 1 billion 537.3 million out of which HRK 1 billion 121.6 million relates to trade payables and liabilities to related parties and HRK 386.6 million to indebtedness (HRK 384.4 million to short term loans and HRK 2.2 million to finance lease).

Trade payables and liabilities to related parties are higher for HRK 48.3 million, or 4.50%, comparing to the beginning of the year.

Total loans liabilities of the Group amount to HRK 398.3 million which is increase of HRK 44.3 million comparing to the beginning of the year. Out of the total loan liabilities, HRK 13.9 million relates to long term loans and HRK 384.4 million to short term loans. Short term indebtedness of Medika has increased for the liquidity purposes.

Key events

Total pharmaceutical market in the first three months of 2016 has increased comparing to the same period of previous year. At the same time, sales of Medika have increased more comparing to the market increase, which resulted in higher market share in 2016.

In equity there was change in treasury shares and capital reserves due to the granting of treasury shares to the management.

Total indebtedness has increased for the liquidity purposes.

Ljekarna Smilja Bagat was merged and both Ljekarna Maja Mučaji and Ljekarna Mirija Bohunicki have started operating in the Group Prima Pharme.

Expected future development of the Group

The Company will continue with its core business: distribution of medicinal products and medical devices will strongly develop operations with products that make the core business of the firm.

Development strategy of Prima Pharme is to expand network of pharmacies on whole territory of Croatia.

Treasury shares

As at 31.03.2016, Medika holds 955 treasury shares.

Subsidiaries and associates

The Company has subsidiaries Zdravstvena ustanova Ljekarne Prima Pharme and Put stinica d.o.o. Both subsidiaries are fully owned by the Company.

ZU Ljekarne Prima Pharme has 100% of ownership in subsidiaries ZU Ljekarne Delonga, ZU Ljekarne Ines Škoko, ZU Ljekarne Atalić, Ljekarna Mirela Klunić and associate ZU Ljekarne Jagatić in which it holds 49% of ownership.

Put stinica d.o.o. has 100% of ownership in subsidiary Primus nekretnine d.o.o.

Related parties

The company with major voting rights, Mavota d.o.o. owns 47.38% of the Company and has 48.93% of shares with voting rights.

Pliva Hrvatska d.o.o., Zagreb owns 25.32% of the Company and has 26.15% of the voting rights. Given the share in the ownership and business transactions with the Company, Pliva Hrvatska has significant influence on the current operations of the Company.

Financial risks and exposure to price risk, credit risk, liquidity and cash flow risk

Within financial risks, foreign exchange risk is significant. The Group's purchase of goods is partly realised on the foreign market. The Group is therefore exposed to foreign exchange risk arising from various changes in foreign exchange rates mainly linked to the EUR.

The Company has part of assets which are interest-bearing so the Company's income and operating cash flows are dependent of changes in market interest rates.

The Company's interest rate risk arises from short term and long term given loans and borrowings with variable interest rates. Borrowings with fixed interest rates expose the Company to the fair value interest rate risk exposure.

The Company does not use derivative instruments to actively hedge cash flow and fair value interest rate risk exposure. However, the Company continuously monitors changes in interest rates. Various scenarios are simulated taking into account refinancing, renewal of existing positions and alternative financing.

Price risk arises from a continuous decrease in the price of HZZO's List of medicinal products and administrative approach in determining prices and margins of medicinal products. To lower this risk, the Company focused on increase of variety of products which are not limited by law in respect of the price of the product.

Majority of the credit risk relates to trade receivables. Credit risk is higher when dealing with pharmacies, which have potential going concern issue. However, hospitals which have longer collection period do not have a going concern issue and collection issue.

The most significant risk within market risks is a long collection period of receivables, especially HZZO and HZZO related receivables. Therefore, a significant amount of working capital is not available what has an influence on cash flows and timely settlement of Medika liabilities.

As these receivables are directly or indirectly related to the receivables from the State institutions, the collection of these receivables should not be classified as a risk. This increases the need for additional financing, which increases finance expenses.

Jasminko Herceg, dipl.oec.
Director


Medika d.d.
Z A G R E B, Caprićka

Appendix 1.

Reporting period:

1.1.2016.

do

31.3.2016.

Quarterly financial statements TFI-POD

Registration number (MB): 03209741

Identification number of company (MBS): 080027531

Personal identification number (OIB): 94818858923

Issuer: **MEDIKA d.d.**

Postal code and city: 10000

ZAGREBAddress: **CAPRAŠKA 1**e-mail: **medika.uprava@medika.hr**web page: **www.medika.hr**Code and name of municipality/city: 133 **ZAGREB**Code and county name: 21 **GRAD ZAGREB**Number of employees: 805
(end of reporting period)Consolidated statements: **YES**

NKD code: 4646

Consolidated entities (according to IFRS):

Headquarters:

MB:

ZU Ljekarne Prime Pharme**Split****0694975****ZU Ljekarne Delonga****Okrug Gornji****1605747****ZU Ljekarne Ines Škoko****Zagreb****02708396****ZU Ljekarne Atalić****Osijek****0845124****Ljekarna Klunić****Pula****80072372****Ljekarna Mučaji****Zadar****80384889**

Bookkeeping service:

Contact person: **RADMILOVIĆ DIJANA**

(only name of the contact person)

Telephone number: **012412551**Fax: **012371441**e-mail: **medika.uprava@medika.hr**Name: **HERCEG JASMINKO**

(authorised person)

Documentation for publishing:

1. Financial statements (Balance sheet, Profit and loss account, Cash flow statements, Statements of changes in equity and Notes to financial statements)
2. Interim report,
3. Statement of Liability.

M.P.

3 Medika d.o.o.
 ZAGREB, Capraška
 (signature of authorised person)

BALANCE SHEET
balance as at 31.03.2016.

Issuer: MEDIKA d.d.			
Description	AOP mark	Previous period	Current period
1	2	3	4
ASSETS			
A) RECEIVABLES FOR SUBSCRIBED BUT NOT PAID-IN CAPITAL	001		
B) NON-CURRENT ASSETS (003+010+020+029+033)	002	417.301.171	423.588.475
I. INTANGIBLE ASSETS (004 to 009)	003	193.205.667	196.917.104
1. Research and development	004		
2. Concessions, patents, licences, trademarks, software and other rights	005	121.806.977	121.463.008
3. Goodwill	006	69.520.289	75.045.184
4. Advances for intangible assets	007		
5. Intangible assets under construction	008	1.878.401	408.912
6. Other intangible assets	009		
II. TANGIBLE ASSETS (011 to 019)	010	191.254.440	192.493.803
1. Land	011	25.226.916	25.226.916
2. Buildings	012	136.672.721	135.450.035
3. Equipment and machinery	013	12.802.474	12.909.308
4. Furniture, fittings and vehicles	014	13.518.410	12.253.488
5. Biological assets	015	6.555	64.208
6. Advances for tangible assets	016	2.196.914	5.761.523
7. Tangible assets under construction	017		
8. Other tangible assets	018	830.450	828.325
9. Investment property	019		
III. NON-CURRENT FINANCIAL ASSETS (021 to 028)	020	29.820.352	31.147.932
1. Investment in subsidiaries and associates	021	21.120.401	21.371.196
2. Loans to related parties	022		
3. Loans given to minority interest	023		
4. Loans given to participating parties	024		
5. Investment in securities	025		
6. Loans given, deposits and similar	026	8.699.951	9.776.736
7. Other non-current financial assets	027		
8. Investments at equity method	028		
IV. RECEIVABLES (030 to 032)	029	1.196.963	1.196.963
1. Receivables from related parties	030		
2. Receivables for credit sales	031		
3. Other receivables	032	1.196.963	1.196.963
V. DEFERRED TAX ASSET	033	1.823.749	1.832.673
C) CURRENT ASSETS (035+043+050+058)	034	1.518.171.670	1.618.634.031
I. INVENTORY (036 To 042)	035	266.292.251	278.652.265
1. Raw material	036	559.931	617.132
2. Work in progress	037		
3. Finished products	038		
4. Trade goods	039	261.478.227	275.433.400
5. Advances for inventories	040	4.254.093	2.601.733
6. Non-current assets available for sale	041		
7. Biological assets	042		
II. RECEIVABLES (044 to 049)	043	1.009.302.620	1.121.259.230
1. Receivables from related parties	044	13.347.799	15.521.565
2. Trade receivables	045	987.749.144	1.097.586.743
3. Receivables from participating parties	046		
4. Receivables from employees	047	1.799.110	1.793.159
5. Receivables from the state and other institutions	048	3.884.222	2.351.724
6. Other receivables	049	2.522.345	4.006.039
III. CURRENT FINANCIAL ASSETS (051 to 057)	050	187.674.250	207.251.158
1. Investment in subsidiaries and associates	051		
2. Loans to related parties	052		
3. Equity investments	053		
4. Loans given to participating parties	054		
5. Investment in securities	055		
6. Loans given, deposits and similar	056	187.674.250	207.251.158
7. Other financial assets	057		
IV. CASH IN BANK AND ON HAND	058	54.902.549	11.471.378
D) PREPAID EXPENSES AND ACCRUED INCOME	059	2.777.795	1.625.045
E) TOTAL ASSETS (001+002+034+059)	060	1.938.250.636	2.043.847.551
G) OFF BALANCE SHEET ITEMS	061	131.451.416	145.018.826

EQUITY AND LIABILITIES			
A) CAPITAL AND RESERVES (063+064+065+071+072+075+078)	062	452,112,596	467,243,725
I. SHARE CAPITAL	063	196,261,000	196,261,000
II. CAPITAL RESERVES	064	-8,652,683	-8,312,744
III. RESERVES FROM RETAINED EARNINGS (066+067-068+069+070)	065	89,677,247	90,377,306
1. Legal reserves	066	15,991,539	15,991,539
2. Reserves for treasury shares	067	51,286,174	51,286,174
3. Treasury shares	068	9,396,956	8,696,897
4. Statutory reserves	069		
5. Other reserves	070	31,796,490	31,796,490
IV. REVALUATION RESERVES	071		
V. RETAINED EARNINGS OR ACCUMULATED LOSS (073-074)	072	129,693,028	174,827,033
1. Retained earnings	073	129,693,028	174,827,033
2. Accumulated loss	074		
VI. PROFIT OR LOSS FOR THE PERIOD (076-077)	075	45,134,004	14,091,130
1. Profit for the period	076	45,134,004	14,091,130
2. Loss for the period	077		
VII. MAJORITY INTERESTS	078		
B) PROVISIONS (080 To 082)	079	1,216,759	1,216,759
1. Provisions for retirement, severance payment and similar	080	1,216,759	1,216,759
2. Tax provisions	081		
3. Other provisions	082		
C) NON-CURRENT LIABILITIES (084 to 092)	083	36,927,624	36,502,107
1. Liabilities to related parties	084		
2. Borrowings and deposits	085		
3. Liabilities to banks and other financial institutions	086	19,452,682	19,027,165
4. Liabilities for advances received	087		
5. Trade payables	088		
6. Liabilities for securities	089		
7. Liabilities to participating parties	090		
8. Other non-current liabilities	091		
9. Deferred tax liability	092	17,474,942	17,474,942
D) CURRENT LIABILITIES (094 to 105)	093	1,447,068,677	1,537,312,666
1. Liabilities to related parties	094	114,785,187	122,298,352
2. Borrowings and deposits	095		
3. Liabilities to banks and other financial institutions	096	342,580,912	386,595,344
4. Liabilities for advances received	097	3,144,574	55,372
5. Trade payables	098	958,479,423	999,289,276
6. Liabilities for securities	099		
7. Liabilities to participating parties	100		
8. Liabilities to employees	101	9,531,536	8,141,648
9. Liabilities for taxes and contributions	102	12,726,327	12,556,494
10. Dividend payables	103	11,564	11,564
11. Liabilities for non-current assets available for sale	104		
12. Other current liabilities	105	5,809,154	8,364,616
E) DEFERRED INCOME AND ACCRUED EXPENSES	106	924,980	1,572,294
F) TOTAL EQUITY AND LIABILITIES (062+079+083+093+106)	107	1,938,250,636	2,043,847,551
G) OFF BALANCE SHEET ITEMS	108	131,451,416	145,018,826
SUPPLEMENT TO BALANCE SHEET (for consolidated financial statements)			
A) CAPITAL AND RESERVES			
1. Attributable to equity holders	109	452,112,596	467,243,725
2. Attributable to minority interest	110		

Note 1.: Supplement to balance sheet is filled for consolidated financial statements.

PROFIT AND LOSS
for period from 01.01.2016. to 31.03.2016.

Issuer: MEDIKA d.d.

Description	AOP mark	Previous period		Current period	
		Cumulative	Quarter	Cumulative	Quarter
1	2	3	4	5	6
I. OPERATING REVENUES (112+113)	111	612.720.402	612.720.402	667.243.075	667.243.075
1. Revenues from sale	112	605.260.914	605.260.914	661.795.805	661.795.805
2. Other operating revenues	113	7.459.488	7.459.488	5.447.270	5.447.270
II. OPERATING EXPENSES (115+116+120+124+125+126+129+130)	114	605.225.618	605.225.618	655.454.043	655.454.043
1. Change in value of work in progress and finished goods	115				
2. Material expenses (117 to 119)	116	564.880.289	564.880.289	615.325.542	615.325.542
a) Raw materials	117	3.070.475	3.070.475	3.031.052	3.031.052
b) Cost of goods sold	118	553.903.681	553.903.681	604.228.588	604.228.588
c) Other expenses	119	7.906.133	7.906.133	8.065.902	8.065.902
3. Employee expenses (121 to 123)	120	24.415.913	24.415.913	25.183.005	25.183.005
a) Net salaries	121	14.488.238	14.488.238	14.924.836	14.924.836
b) Tax and contributions from salaries	122	6.430.199	6.430.199	6.730.973	6.730.973
c) Contributions on salaries	123	3.497.476	3.497.476	3.527.196	3.527.196
4. Depreciation and amortization	124	2.831.493	2.831.493	3.568.477	3.568.477
5. Other expenses	125	10.310.109	10.310.109	8.221.098	8.221.098
6. Impairment (127+128)	126	2.787.814	2.787.814	3.155.921	3.155.921
a) of non-current assets (financial assets excluded)	127				
b) of current assets (financial assets excluded)	128	2.787.814	2.787.814	3.155.921	3.155.921
7. Provisions	129				
8. Other operating expenses	130				
III. FINANCE INCOME (132 to 136)	131	5.194.892	5.194.892	11.788.546	11.788.546
1. Interests, foreign exchanges and dividend from related parties	132	346.107	346.107	250.794	250.794
2. Interests, foreign exchanges and dividend from non-related parties	133	4.848.585	4.848.585	11.537.752	11.537.752
3. Share of profit from associate	134				
4. Unrealised gains	135				
5. Other financial income	136				
IV. FINANCE EXPENSES (138 to 141)	137	3.785.566	3.785.566	5.326.438	5.326.438
1. Interests, foreign exchanges and dividend from related parties	138				
2. Interests, foreign exchanges and dividend from non-related parties	139	83.944	83.944		
3. Unrealised losses	140	3.701.622	3.701.622	5.326.438	5.326.438
4. Other finance expenses	141				
V. SHARE OF PROFIT FROM ASSOCIATE	142				
VI. SHARE OF LOSS FROM ASSOCIATE	143				
VII. EXTRAORDINARY - OTHER INCOME	144				
VIII. EXTRAORDINARY - OTHER EXPENSES	145				
IX. TOTAL INCOME (111+131+142 + 144)	146	617.915.094	617.915.094	679.031.621	679.031.621
X. TOTAL EXPENSES (114+137+143 + 145)	147	609.011.184	609.011.184	660.780.481	660.780.481
XI. PROFIT OR LOSS BEFORE TAX (146-147)	148	8.903.910	8.903.910	18.251.140	18.251.140
1. Profit before tax (146-147)	149	8.903.910	8.903.910	18.251.140	18.251.140
2. Loss before tax (147-146)	150	0	0	0	0
XII. INCOME TAX	151	2.414.039	2.414.039	4.160.010	4.160.010
XIII. PROFIT OR LOSS FOR THE PERIOD (148-151)	152	6.489.871	6.489.871	14.091.130	14.091.130
1. Profit for the period (149-151)	153	6.489.871	6.489.871	14.091.130	14.091.130
2. Loss for the period (151-148)	154	0	0	0	0

SUPPLEMENT TO PROFIT AND LOSS (for consolidated financial statements)

XIV. PROFIT OR LOSS FOR THE PERIOD

1. Attributable to equity holders	155	6.489.871	6.489.871	14.091.130	14.091.130
2. Attributable to minority interest	156				

OTHER COMPREHENSIVE INCOME REPORT (for IFRS reporting)

I. PROFIT OR LOSS FOR THE PERIOD (= 152)	157	6.489.871	6.489.871	14.091.130	14.091.130
--	-----	-----------	-----------	------------	------------

II. OTHER COMPREHENSIVE PROFIT/LOSS BEFORE TAX (159 to 165)

1. Exchange differences on translation of foreign operations	159				
2. Changes in revaluation reserves for non-current tangible and intangible assets	160				
3. Profit or loss from revaluation of financial assets available for sale	161				
4. Gains or losses from efficient cash flow hedging	162				
5. Gains or losses from efficient hedge of net investment abroad	163				
6. Share in other comprehensive profit/loss of associates	164				
7. Actuarial gains/losses on defined benefit plans	165				

III. TAX ON OTHER COMPREHENSIVE INCOME FOR THE PERIOD

166					
-----	--	--	--	--	--

IV. NET OTHER COMPREHENSIVE PROFIT OR LOSS FOR THE PERIOD (158-166)

167	0	0	0	0	0
-----	---	---	---	---	---

V. COMPREHENSIVE PROFIT OR LOSS FOR THE PERIOD (157+167)

168	6.489.871	6.489.871	14.091.130	14.091.130	
-----	-----------	-----------	------------	------------	--

APPENDIX to Other comprehensive income report (to be filled for consolidated financial statements)

VI. COMPREHENSIVE PROFIT OR LOSS

1. Attributable to equity holders	169	6.489.871	6.489.871	14.091.130	14.091.130
2. Attributable to minority interest	170				

STATEMENT OF CASH FLOW - Indirect method
for period from 01.01.2016. to 31.03.2016.

Issuer: MEDIKA d.d.			
Description	AOP mark	Previous period	Current period
1	2	3	4
CASH FLOW FROM OPERATING ACTIVITIES			
1. Profit before tax	001	8.903.910	18.251.141
2. Depreciation and amortisation	002	2.831.493	3.568.477
3. Increase of current liabilities	003	71.801.203	46.229.557
4. Decrease of current receivables	004		
5. Decrease of inventories	005		
6. Other increase of cash flow	006		
I. Total increase of cash flow from operating activities (001 to 006)	007	83.536.606	68.049.175
1. Decrease of current liabilities	008		
2. Increase of current receivables	009	134.735.327	111.956.609
3. Increase of inventories	010	2.395.424	12.360.015
4. Other decrease of cash flow	011	35.159.433	27.263.429
II. Total decrease of cash flow from operating activities (008 to 011)	012	172.290.184	151.580.053
A1) NET INCREASE OF CASH FLOW FROM OPERATING ACTIVITIES (007-012)	013	0	0
A2) NET DECREASE OF CASH FLOW FROM OPERATING ACTIVITIES (012-007)	014	88.753.578	83.530.878
CASH FLOW FROM INVESTING ACTIVITIES			
1. Proceeds from sale of tangible and intangible assets	015	261.700	733.916
2. Proceeds from sale of equity and debt securities	016		
3. Interest received	017	3.542.261	4.166.549
4. Dividends received	018		
5. Other proceeds from investing activities	019		
III. Total proceeds from investing activities (015 to 019)	020	3.803.961	4.900.465
1. Purchase of tangible and intangible assets	021	6.672.664	8.519.276
2. Purchase of equity and debt securities	022		
3. Other purchases resulting from investing activities	023		
IV. Total purchases resulting from investing activities (021 to 023)	024	6.672.664	8.519.276
B1) NET INCREASE OF CASH FLOW FROM INVESTING ACTIVITIES (020-024)	025	0	0
B2) NET DECREASE OF CASH FLOW FROM INVESTING ACTIVITIES (024-020)	026	2.868.703	3.618.811
CASH FLOW FROM FINANCING ACTIVITIES			
1. Proceeds from issuance of equity and debt securities	027		
2. Proceeds from borrowings	028	91.114.751	217.000.000
3. Other proceeds from financing activities	029		
V. Total proceeds from financing activities (027 to 029)	030	91.114.751	217.000.000
1. Repayments of borrowings	031	49.464.989	172.664.435
2. Dividends paid	032		
3. Repayments of finance lease	033	518.160	617.047
4. Purchase of treasury shares	034		
5. Other purchases resulting from financing activities	035		
VI. Ukupno novčani izdaci od financijskih aktivnosti (031 to 035)	036	49.983.149	173.281.482
C1) NET INCREASE OF CASH FLOW FROM FINANCING ACTIVITIES (030-036)	037	41.131.602	43.718.518
C2) NET DECREASE OF CASH FLOW FROM FINANCING ACTIVITIES (036-030)	038	0	0
Total increase of cash flow (013 – 014 + 025 – 026 + 037 – 038)	039	0	0
Total decrease of cash flow (014 – 013 + 026 – 025 + 038 – 037)	040	50.490.679	43.431.171
Cash and cash equivalents at beginning of the period	041	81.101.077	54.902.549
Increase of cash and cash equivalents	042		
Decrease of cash and cash equivalents	043	50.490.679	43.431.171
Cash and cash equivalents at end of the period	044	30.610.398	11.471.378

STATEMENT OF CHANGES IN EQUITY
for period from **1.1.2016.** to **31.3.2016.**

Description	AOP mark	Previous period	Current period
1	2	3	4
1. Share capital	001	196.261.000	196.261.000
2. Capital reserves	002	-8.652.683	-8.312.744
3. Reserves from retained earnings	003	89.677.247	90.377.306
4. Retained earnings or accumulated loss	004	129.693.028	174.827.033
5. Profit or loss for the period	005	45.134.004	14.091.130
6. Revaluation of tangible assets	006		
7. Revaluation of intangible assets	007		
8. Revaluation of financial assets available for sale	008		
9. Other revaluation	009		
10. Total capital and reserves (AOP 001 to 009)	010	452.112.596	467.243.725
11. Foreign exchanges from the foreign investments	011		
12. Current and deferred tax (part)	012		
13. Cash flow hedge	013		
14. Changes of accounting policies	014		
15. Correction of material mistakes from previous period	015		
16. Other changes of equity	016		
17. Total increase or decrease of equity (AOP 011 to 016)	017	0	0
17 a. Attributable to equity holders	018	452.112.596	467.243.725
17 b. Attributable to minority interest	019		

Balances that decrease equity are presented with the minus

Data in AOP 001 to 009 are presented as the balance as at balance sheet date

Zagreb, 28 April 2016

Pursuant to the articles 401. to 410. of the Capital market Law (Official Gazette 88/08, 146/08, 74/09, 54/13, 159/13, 18/15 and 110/15) Director Jasminko Herceg provides

STATEMENT OF LIABILITY FOR PREPARING FINANCIAL STATEMENTS OF ISSUER

Temporary unaudited unconsolidated and consolidated financial statements of Medika d.d. have been prepared pursuant to the International Financial Reporting Standards (IFRS) and Croatian Accounting Law.

Temporary unaudited unconsolidated and consolidated financial statements for the period 01 January to 31 December 2015 present complete and fair view of assets and liabilities, profit and loss, financial position and operations of the Company and the Group.

The interim management report for the temporary unaudited financial statements for the period 01 January to 31 December 2015 presents true and fair presentation of development and results of the operations and position of the Company and the Group with description of significant risks and uncertainties for the Company and the Group.

Jasminko Herceg
Director


ZAGREB Capital